SHPH vs. TFFP, ADIL, PULM, CVKD, XBIO, ADXS, LIXT, KTTA, HILS, and VCNX
Should you be buying Shuttle Pharmaceuticals stock or one of its competitors? The main competitors of Shuttle Pharmaceuticals include TFF Pharmaceuticals (TFFP), Adial Pharmaceuticals (ADIL), Pulmatrix (PULM), Cadrenal Therapeutics (CVKD), Xenetic Biosciences (XBIO), Ayala Pharmaceuticals (ADXS), Lixte Biotechnology (LIXT), Pasithea Therapeutics (KTTA), Hillstream BioPharma (HILS), and Vaccinex (VCNX). These companies are all part of the "pharmaceutical preparations" industry.
TFF Pharmaceuticals (NASDAQ:TFFP) and Shuttle Pharmaceuticals (NASDAQ:SHPH) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, community ranking, analyst recommendations, media sentiment, profitability, risk and earnings.
TFF Pharmaceuticals received 67 more outperform votes than Shuttle Pharmaceuticals when rated by MarketBeat users.
In the previous week, TFF Pharmaceuticals had 1 more articles in the media than Shuttle Pharmaceuticals. MarketBeat recorded 1 mentions for TFF Pharmaceuticals and 0 mentions for Shuttle Pharmaceuticals. Shuttle Pharmaceuticals' average media sentiment score of 0.00 equaled TFF Pharmaceuticals'average media sentiment score.
Shuttle Pharmaceuticals has lower revenue, but higher earnings than TFF Pharmaceuticals. Shuttle Pharmaceuticals is trading at a lower price-to-earnings ratio than TFF Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
TFF Pharmaceuticals presently has a consensus price target of $72.00, indicating a potential upside of 3,296.23%. Given Shuttle Pharmaceuticals' higher possible upside, equities analysts clearly believe TFF Pharmaceuticals is more favorable than Shuttle Pharmaceuticals.
15.3% of TFF Pharmaceuticals shares are held by institutional investors. Comparatively, 4.6% of Shuttle Pharmaceuticals shares are held by institutional investors. 5.6% of TFF Pharmaceuticals shares are held by insiders. Comparatively, 40.6% of Shuttle Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
TFF Pharmaceuticals has a beta of 1.44, suggesting that its share price is 44% more volatile than the S&P 500. Comparatively, Shuttle Pharmaceuticals has a beta of -1.18, suggesting that its share price is 218% less volatile than the S&P 500.
Shuttle Pharmaceuticals has a net margin of 0.00% compared to Shuttle Pharmaceuticals' net margin of -2,897.95%. TFF Pharmaceuticals' return on equity of -112.18% beat Shuttle Pharmaceuticals' return on equity.
Summary
TFF Pharmaceuticals beats Shuttle Pharmaceuticals on 8 of the 14 factors compared between the two stocks.
Get Shuttle Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for SHPH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SHPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Shuttle Pharmaceuticals Competitors List
Related Companies and Tools
